The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Safety results from a randomized trial of perioperative epirubicin, cisplatin plus capecitabine (ECX) with or without bevacizumab (B) in patients (pts) with gastric or type II/III oesophagogastric junction (OGJ) adenocarcinoma.
A. F. C. Okines
Honoraria - Roche
Other Remuneration - Amgen; Bayer; Roche
R. E. Langley
Research Funding - Medical Research Council
L. C. Thompson
Research Funding - Medical Research Council
S. P. Stenning
Research Funding - Medical Research Council
L. Stevenson
Research Funding - Medical Research Council
S. Falk
Honoraria - Amgen; Roche
Research Funding - Roche
M. T. Seymour
Research Funding - Roche
Other Remuneration - Roche
F. Y. Coxon
Research Funding - Roche
G. W. Middleton
No relevant relationships to disclose
D. Smith
No relevant relationships to disclose
L. Evans
No relevant relationships to disclose
S. Slater
No relevant relationships to disclose
J. S. Waters
No relevant relationships to disclose
D. Ford
No relevant relationships to disclose
M. Hall
No relevant relationships to disclose
T. Iveson
Honoraria - Roche
Research Funding - Pfizer; Roche
R. D. Petty
No relevant relationships to disclose
C. Plummer
Honoraria - Roche
W. Allum
No relevant relationships to disclose
D. Cunningham
Consultant or Advisory Role - Amgen; Roche (U)
Research Funding - Amgen; Merck Serono; Roche; Sanofi